Echo-guided percutaneous septal ablation for symptomatic hypertrophic obstructive cardiomyopathy: 7 years of experience.

[1]  C. Tracy,et al.  American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice G , 2003, European heart journal.

[2]  P. Grayburn,et al.  Comparison of successful and failed alcohol septal ablations for obstructive hypertrophic cardiomyopathy. , 2003, The American journal of cardiology.

[3]  H. Kuhn,et al.  Role of Transcoronary Ablation of Septal Hypertrophy in Patients With Hypertrophic Cardiomyopathy, New York Heart Association Functional Class III or IV, and Outflow Obstruction Only Under Provocable Conditions , 2002, Circulation.

[4]  W. Edwards,et al.  Anatomy of the first septal perforating artery: a study with implications for ablation therapy for hypertrophic cardiomyopathy. , 2001, Mayo Clinic proceedings.

[5]  H. Seggewiss.  Current status of alcohol septal ablation for patients with hypertrophic cardiomyopathy , 2001, Current cardiology reports.

[6]  P. Elliott,et al.  Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. , 2000, Journal of the American College of Cardiology.

[7]  L. Faber,et al.  Targeting percutaneous transluminal septal ablation for hypertrophic obstructive cardiomyopathy by intraprocedural echocardiographic monitoring. , 2000, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[8]  L. Faber,et al.  Percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy: long term follow up of the first series of 25 patients , 2000, Heart.

[9]  H. Kuhn,et al.  Acute and long-term results after transcoronary ablation of septal hypertrophy (TASH). Catheter interventional treatment for hypertrophic obstructive cardiomyopathy. , 1999, European heart journal.

[10]  U. Gleichmann,et al.  Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: results with respect to intraprocedural myocardial contrast echocardiography. , 1998, Circulation.

[11]  M. Verani,et al.  Echocardiography-guided ethanol septal reduction for hypertrophic obstructive cardiomyopathy. , 1998, Circulation.

[12]  D. Fassbender,et al.  Guiding of Percutaneous Transcoronary Septal Myocardial Ablation in Hypertrophic Obstructive Cardiomyopathy by Myocardial Contrast Echocardiography , 1998 .

[13]  P. Grayburn,et al.  Spontaneous Variability of Left Ventricular Outflow Tract Gradient in Hypertrophic Obstructive Cardiomyopathy , 1998, Circulation.

[14]  D. Fassbender,et al.  Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: acute results and 3-month follow-up in 25 patients. , 1998, Journal of the American College of Cardiology.

[15]  U. Gleichmann,et al.  Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: clinical and non-invasive follow-up results , 1998 .

[16]  H. Kuhn,et al.  Induction of subaortic septal ischaemia to reduce obstruction in hypertrophic obstructive cardiomyopathy. Studies to develop a new catheter-based concept of treatment. , 1997, European heart journal.

[17]  E. Braunwald,et al.  Induced septal infarction: a new therapeutic strategy for hypertrophic obstructive cardiomyopathy. , 1997, Circulation.

[18]  D. Harrington,et al.  Nonsurgical septal reduction for hypertrophic obstructive cardiomyopathy: outcome in the first series of patients. , 1997, Circulation.

[19]  W. Williams,et al.  Hypertrophic cardiomyopathy. Clinical spectrum and treatment. , 1995, Circulation.

[20]  U. Sigwart.  Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy , 1995, The Lancet.